Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | PWRM,ICAD,JASO Stock Report From PennyToBuck.comPWRM is now available for $0.038 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout.
By: Justin Handy POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB) PWRM is now available for $0.038 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum. PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover: Processes - The manner in which the discoveries are made and tests developed Discoveries - Protein disease footprints, Products - Early detection tests, Biomarkers, and Drug Targets The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance: The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below: Two of Power3 Medical Areas of Research Breast Cancer Breast CancerPower3’ More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer NAF footprints for individualized therapy Neurodegenerative Diseases - ALS (Lou Gehrig’s Disease), Alzheimer’s Disease, Parkinson’s Disease, Other Neurological Disorders Neurodegenerative DiseasesPower3’ Blood serum biomarkers and drug targets for neurodegenerative disease Resistance to Chemotherapy Resitance to ChemotherapyPower3’ Biomarkers and drug targets for treatment and monitoring of drug resistance Continue your research at www.power3medical.com JA Solar Holdings Co., Ltd. , a leading manufacturer of high-performance solar power products, today announced it has entered into supply agreements with Solar-Fabrik AG. Under the terms of the agreements, JA Solar is expected to supply Solar-Fabrik with approximately 70MW of photovoltaic products. Shipment has already started and will continue through the end of 2010. The supply agreements further strengthen the strong partnership between the two companies that began in 2008. Both JA Solar and Solar-Fabrik are committed to work together for future growth. About JA Solar Holdings Co., Ltd. JA Solar Holdings Co., Ltd. is a leading manufacturer of high-performance solar power products. The company sells its products to solar manufacturers worldwide, who assemble and integrate solar cells into modules and systems that convert sunlight into electricity for residential, commercial, and utility-scale power generation. For more information, please visit About Solar-Fabrik AG Founded in 1996 and based in Freiburg im Breisgau, Germany, Solar-Fabrik AG is among Europe's leading solar power companies. The company manufactures its products in Freiburg and is certified according to DIN ISO 9001 and 14001. Well defined quality management is a prerequisite for excellent system yields. This includes the selection of high-quality materials, state-of-the- iCAD, Inc. , an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that the Company will release financial results for the second quarter and six months ended June 30, 2010, following the close of the market on Wednesday, July 28, 2009. Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern Time on Thursday, July 29, 2010 to discuss second quarter and six months 2010 financial results and to answer questions. About iCAD, Inc. iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography) Continue your research at www.icadmed.com *********************************** For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/ *********************************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB) # # # Justin Handy justin@crownequityholdings.com Main: 702-448-1543 Fax: 702-479-7151 Toll Free: 1-877-854-6797 5440 W. Sahara Ave. Suite 205 Las Vegas,Nevada,89146 End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
